Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
10.05
+0.80 (8.65%)
At close: Jun 25, 2025, 4:00 PM
10.15
+0.10 (1.00%)
Pre-market: Jun 26, 2025, 5:41 AM EDT
Capricor Therapeutics Revenue
Capricor Therapeutics had revenue of $17.36M in the twelve months ending March 31, 2025, down -35.92% year-over-year. In the year 2024, Capricor Therapeutics had annual revenue of $22.27M, down -11.55%.
Revenue (ttm)
$17.36M
Revenue Growth
-35.92%
P/S Ratio
22.45
Revenue / Employee
$108,522
Employees
160
Market Cap
459.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
CAPR News
- 1 day ago - FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy - Benzinga
- 1 day ago - US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
- 2 days ago - Why Is Capricor Therapeutics Stock Trading Lower On Monday? - Benzinga
- 5 days ago - Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients - Benzinga
- 5 days ago - Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy - GlobeNewsWire
- 8 days ago - Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program - GlobeNewsWire
- 14 days ago - Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement - Seeking Alpha
- 14 days ago - Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program - GlobeNewsWire